SOTIO, a clinical-stage immuno-oncology company owned by PPF Group, announced a license and option agreement with Synaffix B.V., a Lonza company, to develop next-generation antibody-drug conjugates for the treatment of solid tumors.
October 16, 2023
· 5 min read
